We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights: Tilray, Cronos, Canopy Growth, GW Pharmaceuticals and Constellation Brands
Read MoreHide Full Article
For Immediate Release
Chicago, IL –October 24, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Tilray Inc. (TLRY - Free Report) ,Cronos Group Inc. (CRON - Free Report) , Canopy Growth Corp. (CGC - Free Report) , GW Pharmaceuticals plc and Constellation Brands (STZ - Free Report) .
Here are highlights from Tuesday’s Analyst Blog:
Marijuana Stocks Plummet to All-Time Lows: What’s Next?
Over the last few days, share prices of major marijuana stocks have plummeted to their worst in the trailing eight months. This free fall commenced following the legalization of marijuana for recreational use in Canada on Oct 17.
Legalization Considered a Boon for the Industry
Notably, legalization has long been considered a boon for the marijuana industry. Canada has become the first major world economy and the second country after Uruguay to legalize recreational use of marijuana.
In the United States, nine states and Washington, D.C., have currently legalized recreational marijuana, while 29 states have legalized medical weed. Medical use of marijuana has been legal in Canada since 2001.
Effective Oct 17, Canadians can legally buy and consume marijuana. Growing legalization of recreational or medical marijuana is likely to bolster investors’ confidence in this industry.
Extremely Volatile Industry
Recent plunge in share prices of marijuana stocks is a result of market concerns regarding retailers facing supply shortages in the early days of legalization. Per a recent report by BNN Bloomberg, the pot industry in Canada is struggling with shortages as provincial and private-sector retailers struggle to keep up with the strong demand for recreational cannabis in the country.
Marijuana industry is considered as extremely volatile. Most of these companies are in their early stages of development and characterized as risky one for investors. However, this industry had been providing fabulous returns to investors in 2018 before the legalization in Canada.
Since the industry is in its nascent stage, even a minor negative may become the cause of major stock price fluctuations. The news of supply shortages results in panic selling as investor’s look to offload risky stocks. According to some industry experts, 5-10% share price volatility daily should not be considered as unnatural for this industry.
On Oct 22, shares of major marijuana companies such as Tilray Inc., Cronos Group Inc., Canopy Growth Corp. and GW Pharmaceuticals plc tumbled 15.6%, 12.3%, 11.2% and 2.1%, respectively. Cronos Group and GW Pharmaceuticals carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Strong Market Potential
Research firm Euromonitor has estimated that the American market for legal marijuana products will reach $20 billion by 2020 from mere $5.4 billion in 2015.
According to the Arcview Market Research, the U.S. legal cannabis market is expected to reach $11 billion in consumer spending in 2018, expanding further to $23 billion by 2022. Research firm Cowen projected that the market size of U.S. legal cannabis industry will reach $75 billion in by 2030, surpassing the carbonated soft drink market in 2017.
Many beverage giants have decided to invest in cannabis. Coca-Cola is in talks with Canada’s Aurora Cannabis to develop cannabidiol infused beverages. Recently, Constellation Brands raised its stake to 38% in Canopy Growth after investing $4 billion in the company.
Bottom Line
Marijuana industry has strong potential especially after legalization for recreational and medicinal use. However, extremely volatile nature of this industry remains a primary concern. Consequently, investors should be careful about timing and selection of stocks within this industry.
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +21.9% in 2017, our top stock-picking screens have returned +115.0%, +109.3%, +104.9%, +98.6%, and +67.1%.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - 2017, the composite yearly average gain for these strategies has beaten the market more than 19X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
The Zacks Analyst Blog Highlights: Tilray, Cronos, Canopy Growth, GW Pharmaceuticals and Constellation Brands
For Immediate Release
Chicago, IL –October 24, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Tilray Inc. (TLRY - Free Report) ,Cronos Group Inc. (CRON - Free Report) , Canopy Growth Corp. (CGC - Free Report) , GW Pharmaceuticals plc and Constellation Brands (STZ - Free Report) .
Here are highlights from Tuesday’s Analyst Blog:
Marijuana Stocks Plummet to All-Time Lows: What’s Next?
Over the last few days, share prices of major marijuana stocks have plummeted to their worst in the trailing eight months. This free fall commenced following the legalization of marijuana for recreational use in Canada on Oct 17.
Legalization Considered a Boon for the Industry
Notably, legalization has long been considered a boon for the marijuana industry. Canada has become the first major world economy and the second country after Uruguay to legalize recreational use of marijuana.
In the United States, nine states and Washington, D.C., have currently legalized recreational marijuana, while 29 states have legalized medical weed. Medical use of marijuana has been legal in Canada since 2001.
Effective Oct 17, Canadians can legally buy and consume marijuana. Growing legalization of recreational or medical marijuana is likely to bolster investors’ confidence in this industry.
Extremely Volatile Industry
Recent plunge in share prices of marijuana stocks is a result of market concerns regarding retailers facing supply shortages in the early days of legalization. Per a recent report by BNN Bloomberg, the pot industry in Canada is struggling with shortages as provincial and private-sector retailers struggle to keep up with the strong demand for recreational cannabis in the country.
Marijuana industry is considered as extremely volatile. Most of these companies are in their early stages of development and characterized as risky one for investors. However, this industry had been providing fabulous returns to investors in 2018 before the legalization in Canada.
Since the industry is in its nascent stage, even a minor negative may become the cause of major stock price fluctuations. The news of supply shortages results in panic selling as investor’s look to offload risky stocks. According to some industry experts, 5-10% share price volatility daily should not be considered as unnatural for this industry.
On Oct 22, shares of major marijuana companies such as Tilray Inc., Cronos Group Inc., Canopy Growth Corp. and GW Pharmaceuticals plc tumbled 15.6%, 12.3%, 11.2% and 2.1%, respectively. Cronos Group and GW Pharmaceuticals carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Strong Market Potential
Research firm Euromonitor has estimated that the American market for legal marijuana products will reach $20 billion by 2020 from mere $5.4 billion in 2015.
According to the Arcview Market Research, the U.S. legal cannabis market is expected to reach $11 billion in consumer spending in 2018, expanding further to $23 billion by 2022. Research firm Cowen projected that the market size of U.S. legal cannabis industry will reach $75 billion in by 2030, surpassing the carbonated soft drink market in 2017.
Many beverage giants have decided to invest in cannabis. Coca-Cola is in talks with Canada’s Aurora Cannabis to develop cannabidiol infused beverages. Recently, Constellation Brands raised its stake to 38% in Canopy Growth after investing $4 billion in the company.
Bottom Line
Marijuana industry has strong potential especially after legalization for recreational and medicinal use. However, extremely volatile nature of this industry remains a primary concern. Consequently, investors should be careful about timing and selection of stocks within this industry.
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +21.9% in 2017, our top stock-picking screens have returned +115.0%, +109.3%, +104.9%, +98.6%, and +67.1%.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - 2017, the composite yearly average gain for these strategies has beaten the market more than 19X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
See Them Free>>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
http://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.